N-Acetyl Epitalon Amidate

N-Acetyl Epitalon Amidate Anti-Aging & Longevity Profile

N-Acetyl Epitalon Amidate serves as a foundational element within life extension research, specifically designed to interdict genetic degradation, preserve mitochondrial function, and aggressively target senescent cell buildup.

Pharmacological Profile

Parameter	Value
Molecular Formula	C41H65N11O19
Molecular Mass	1008.0 g/mol
Assay Purity	>99.5%
Appearance	White-to-off-white solid

Figure 1: N-Acetyl Epitalon Amidate Cellular Transduction Representation

Genomic Mechanism of Action

Observations of the exact signaling cascade leading to its theoretical longevity effects:

1. Possesses the same bio-active tetrapetide sequence as standard Epitalon.
2. Features an N-terminal acetyl group and C-terminal amide to prevent exopeptidase degradation.
3. Exponentially increases the compound's stability against enzymatic breakdown.
4. Allows for lower gross dosing while achieving identical telomerase upregulation.
5. Exhibits superior central nervous system penetration.

Figure 2: Empirical Longevity Outcomes & Age Reversal Metrics

Primary Research Vectors

• Study 1: Offers the most bio-available and stable variant of the Khavinson pineal peptide.
• Study 2: Requires less frequent administration intervals due to extended half-life.
• Study 3: Maintains absolutely identical biological cascades as standard Epitalon.

Enhanced Stability & Bioavailability

N-Acetyl Epitalon Amidate represents a chemically modified version of the base epitalon tetrapeptide in which the N-terminus is acetylated and the C-terminus is amidated. These two modifications are standard pharmaceutical chemistry techniques applied to short peptides to dramatically improve their pharmacological properties. The acetyl group blocks aminopeptidase cleavage at the N-terminus, while the amide group prevents carboxypeptidase degradation at the C-terminus. Together, they extend the peptide’s half-life in biological fluids by 3–5 fold compared to unmodified epitalon.

1. N-terminal acetylation neutralizes the positive charge on the alpha-amino group, reducing recognition by aminopeptidase M and other exopeptidases.
2. C-terminal amidation replaces the carboxylate (-COOH) with a carboxamide (-CONH&sub2;), blocking carboxypeptidase A and B activity.
3. The combined modifications increase serum half-life from approximately 2–5 minutes (native epitalon) to an estimated 15–30 minutes.
4. The amide group also enhances hydrogen bonding capacity at the C-terminus, potentially improving receptor binding affinity.
5. Lipophilicity is slightly increased by acetylation, which may modestly improve cellular membrane permeability and intracellular access.

Research Considerations vs. Base Epitalon

• Potency: Modified peptides typically show lower ED50 values (greater potency per milligram) due to reduced proteolytic waste. Researchers may need to adjust doses downward.
• Duration of Action: The extended half-life may allow less frequent dosing intervals while maintaining comparable or superior telomerase activation profiles.
• Cost-Effectiveness: Although the per-milligram cost is higher, the improved bioavailability means less peptide is required per effective dose, potentially offsetting the price difference.
• Reconstitution: N-Acetyl Epitalon Amidate is reconstituted identically to standard epitalon in BAC water. Solubility is comparable.
• Storage: The modifications improve lyophilized shelf stability. Store at −20°C for long-term or 2–8°C for active use.